3-<1-methyl-4-<1-methyl-4-(1-methyl-4-aminopyrrole-2-carboxamido)pyrrole-2-carboxamido>pyrrole-2-carboxamido>propionitrile | 121541-72-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-<1-methyl-4-<1-methyl-4-(1-methyl-4-aminopyrrole-2-carboxamido)pyrrole-2-carboxamido>pyrrole-2-carboxamido>propionitrile
• 英文别名: 3-{1-methyl-4-[1-methyl-4-(1-methyl-4-aminopyrrole-2-carboxamido)pyrrole-2-carboxamido]pyrrole-2-carboxamido}propionitrile；4-amino-N-[5-[[5-(2-cyanoethylcarbamoyl)-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-1-methylpyrrole-2-carboxamide
• CAS: 121541-72-8
• 化学式: C₂₁H₂₄N₈O₃
• 分子量: 436.473
• InChiKey: XJCMGVNIGOMVRI-UHFFFAOYSA-N

物化性质

• 沸点：
  651.8±55.0 °C(Predicted)
• 密度：
  1.38±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  152
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-<1-methyl-4-<1-methyl-4-(1-methyl-4-aminopyrrole-2-carboxamido)pyrrole-2-carboxamido>pyrrole-2-carboxamido>propionitrile 在 sodium hydroxide 、 水 、 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 生成 6-[[5-[[5-[[5-(2-Cyanoethylcarbamoyl)-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]pyridine-3-carboxylic acid
  参考文献：
  名称：

  几何约束的不对称双（聚酰胺）与抗病毒性双霉素的合成。

  摘要：

  分析分别对（AT）4和（AT）5的寡肽小沟结合剂netropsin（I）和distamycin（II）的严格DNA碱基序列识别的结构和立体化学要求导致了对合理的结构修饰，以改变碱基识别。在本文中，我们报告了与天然抗病毒剂双歧霉素在结构上相关且带有非天然（25-27）或天然（31-33）的不对称咪唑并吡咯并双（聚酰胺）的合成）由柔性或刚性接头链接的末端。这是关于在连接的双（聚酰胺）中具有二甲基氨基丙基或am基末端的带有咪唑的结构的合成的首次报道。

  DOI：

  10.1002/1099-0690(200006)2000:11<2095::aid-ejoc2095>3.0.co;2-j
• 作为产物：
  描述：

  methyl 4-<<<4-<<<4-<<(tert-butyloxy)carbonyl>amino>-1-methyl-pyrrol-2-yl>carbonyl>amino>-1-methyl-pyrrol-2-yl>carbonyl>amino>-1-methyl-pyrrole-2-carboxylate 在 盐酸 、 4-二甲氨基吡啶 、 lithium hydroxide 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.5h， 生成 3-<1-methyl-4-<1-methyl-4-(1-methyl-4-aminopyrrole-2-carboxamido)pyrrole-2-carboxamido>pyrrole-2-carboxamido>propionitrile
  参考文献：
  名称：

  Distamycin A 和 2640 类似物的全合成：一种用于发现新的生物活性 DNA 结合剂和开发用于确定相对 DNA 结合亲和力或 DNA 结合序列选择性的快速、高通量筛选的液相组合方法

  摘要：

  描述了远霉素 A 的液相合成的发展及其对 2640 类似物制备的扩展。因此，采用酸/碱液-液萃取进行反应后处理和纯化的液相合成技术用于多步制备偏霉素 A（8 步，40% 总产率）和 2640 类似物的原型库，提供中间体和最终产品在常规反应规模上纯度≥95%。公开了一种简单、快速和高通量的 DNA 结合亲和力筛选的补充开发，该筛选基于来自预结合溴化乙锭置换的荧光损失，适用于评估对 DNA 均聚物或特定序列的相对或绝对结合亲和力。发夹寡核苷酸）。使用发夹寡核苷酸，

  DOI：

  10.1021/ja994192d

文献信息

• Novel linked antiviral and antitumor agents related to netropsin and distamycin: synthesis and biological evaluation
  作者：J. William Lown、Krzysztof Krowicki、Jan Balzarini、Robert A. Newman、Erik De Clercq

  DOI：10.1021/jm00130a024

  日期：1989.10

  have been synthesized which are structurally related to the natural antiviral antitumor antibiotics netropsin and distamycin bearing two such moieties linked by polymethylene bridges. Cytostatic activity against both human and murine tumor cell lines and their in vitro activity against a range of viruses are reported. Enhanced antiviral activity was obtained against vaccinia virus. As a result of the

  合成了一组寡肽，其在结构上与天然抗病毒抗肿瘤抗生素netropsin和distamycin有关，带有通过聚亚甲基桥连接的两个这样的部分。据报道，对人和鼠肿瘤细胞系均具有细胞抑制活性，并且它们对多种病毒具有体外活性。获得了针对牛痘病毒的增强的抗病毒活性。由于引入了多亚甲基接头[（CH2）n，n = 1、2和6-8]，与母体化合物netropsin和distamycin相比，其抗肿瘤和抗痘苗病毒的活性均显着增强。讨论了这些试剂的生物学活性，既涉及其结构差异，也涉及其与双链DNA的小沟结合。
• Structure-activity relationships of pyrrole amidine antiviral antibiotics. 2. Preparation of mono- and tripyrrole derivatives of congocidine
  作者：Meir Bialer、Boris Yagen、Raphael Mechoulam、Yechiel Becker

  DOI：10.1021/jm00184a018

  日期：1980.10

  virus (HSV) replication in cultured cells, and effects on the synthesis of HS DNA in isolated nuclei in vitro, as well as on DNA synthesis by purified HSV DNA polymerase. All synthesized tripyrrole derivatives of congocidine were less cytotoxic and more active than the parent drug in all the three ant iviral tests.

  合成了三种类型的刚果金（1）类似物的代表。测试了它们的细胞毒性，在培养细胞中对单纯疱疹病毒（HSV）复制的抑制以及对离体核中HS DNA合成的影响，以及纯化HSV DNA聚合酶对DNA合成的影响。在所有三个抗病毒试验中，所有合成的刚果金三吡咯衍生物的毒性都比母体药物小，活性更高。
• Design and synthesis of novel distamycin-modified nucleoside analogues as HIV-1 reverse transcriptase inhibitors
  作者：Chao Li、Chunying Ma、Jin Zhang、Ning Qian、Jingjing Ding、Renzhong Qiao、Yufen Zhao

  DOI：10.1016/j.antiviral.2013.12.002

  日期：2014.2

  Design and synthesis of nucleoside analogues have persistently attracted extensive interest because of their potential application in the field of antiviral therapy, and its study also receives additional impetus for improvement in the ProTide technology. Previous studies have made great strides in the design and discovery of monophosphorylated nucleoside analogues as potential kinase-independent antiretrovirals. In this work, a series of nucleoside phosphoramidates modified by distamycin analogues was synthesized and evaluated as nucleoside reverse transcriptase inhibitors (NRTIs) in HIV-1-infected MT-4 and CEM cells, including variations in nucleoside, alkyl moiety, and the structure of distamycin analogues. These compounds exhibited modest potency with the EC50 value in the range of 1.3- to 6.5-fold lower than their corresponding parent drugs in MT-4 cells, which may be attributed to increasing intracellular availability due to the existence of distamycin analogue with favorable hydrophilic-lipophilic equilibrium. Meanwhile, the length of distamycin analogue was considered and assessed as an important factor that could affect antiviral activity and cytotoxicity. Enzymatic and metabolic stability studies have been performed in order to better understand the antiviral behavior of these compounds. The present work revealed the compounds to have a favorable and selective anti-HIV-1 activity in MT-4 and CEM cells, and helped to develop strategies for design and synthesis of effective monophosphorylated nucleoside analogues, which may be applied to antiretroviral research as NRTIs. (C) 2013 Elsevier B.V. All rights reserved.
• US5616606A
  申请人：——

  公开号：US5616606A

  公开（公告）日：1997-04-01
• [EN] OLIGOPEPTIDE ANTIRETROVIRAL AGENTS
  申请人：SYNPHAR LABORATORIES, INC.

  公开号：WO1992013838A1

  公开（公告）日：1992-08-20

  (EN) Oligopeptide antiretroviral agents are represented by formula (I), wherein A is a moiety bearing a positive charge and of a size which avoids steric inhibition of binding of said compound to nucleic acid sequences associated with the cellular activity of retroviruses; R1 is a moiety derived from a dicarboxylic acid; Het is a five-membered heterocyclic moiety; y and z are independently 0, 1, 2 or 3; and x is 0 or 1. These compounds exhibit antiretroviral activity, especially against Human Immunodeficiency Virus (HIV).(FR) Cette invention concerne des agents antirétroviraux oligopeptidiques représentés par la formule (I), dans laquelle A représente une fraction portant une charge positive dont la taille permet d'éviter l'inhibition stérique de liaison dudit composé à des séquences d'acides nucléiques associées à l'activité cellulaire de rétrovirus; R1 représente une fraction dérivée d'un acide dicarboxylique; y et z représentent indépendamment 0, 1, 2, ou 3; et x est égal à 0 ou 1. Les composés présentent une activité antirétrovirale, plus particulièrement contre le virus de l'immunodéficience humaine (VIH).